In August 2022, the U.S. Food and Drug Administration finalized a rule creating a new category of over-the-counter hearing aids that could be sold without a prescription, professional evaluation, or audiologist involvement. The rule took effect in October 2022, and since then, OTC hearing aids have appeared on the shelves of major retail chains and pharmacy networks across the country. The stated goal of the regulation was to improve access to hearing care for the estimated 30 million Americans with hearing loss who were not seeking or obtaining treatment, largely due to cost and convenience barriers. These are legitimate concerns. But the OTC category has also generated significant confusion among consumers about what these products do, who they are appropriate for, and what they cannot replace. That confusion deserves a clinical perspective grounded in what audiology actually involves.
What the OTC Category Was Designed For
The FDA’s OTC hearing aid rule specifically targets adults 18 years and older with perceived mild to moderate hearing loss. The regulatory framework explicitly excludes children, adults with severe or profound hearing loss, and anyone with certain medical conditions — sudden hearing loss, asymmetric hearing loss, active ear pain, drainage, or tinnitus of recent onset — that require medical or audiological evaluation before any intervention. Within its intended scope, the OTC category represents a meaningful expansion of access to basic amplification for adults who are aware they have mild hearing difficulty and want an accessible, affordable starting point.
The key phrase in that framing is “perceived mild to moderate hearing loss.” The regulation is based on the consumer’s self-assessment of their hearing, not on an audiometric evaluation. This is a design feature, not an oversight — the goal was to remove the professional evaluation step for a portion of the population with less severe loss. The clinical problem is that self-assessment of hearing loss is not reliable. Multiple studies have shown that adults systematically underestimate the degree of their hearing loss, particularly in the early and moderate stages when the gradual nature of the decline makes the change difficult to perceive introspectively. A consumer who believes their loss is mild may have moderate or even moderate-severe loss that would not be well-served by an OTC product. A consumer who feels their hearing is “fine except in noisy places” may have documented high-frequency loss that OTC self-fitting cannot adequately address.
The Clinical Case for Professional Evaluation First
The audiological evaluation that precedes a prescription hearing aid fitting is not a formality or a commercial gatekeeping mechanism — it is a diagnostic process with real clinical implications. Approximately 5 to 10 percent of adults who present for audiological evaluation have medically significant pathology identified during the assessment: asymmetric sensorineural hearing loss that warrants imaging to rule out vestibular schwannoma, unilateral conductive loss suggesting otosclerosis or middle ear pathology, sudden sensorineural hearing loss requiring urgent medical management, or aural fullness with low-frequency threshold change consistent with endolymphatic hydrops. None of these conditions are identifiable through self-assessment or OTC product use, and some — particularly sudden hearing loss, which has a narrow window for steroid treatment that may preserve hearing — have time-sensitive implications. An OTC device purchased by someone experiencing the early symptoms of acoustic neuroma does not harm them directly, but it may delay the evaluation that would identify the problem.
Beyond the identification of medical pathology, the audiometric evaluation establishes the specific configuration and degree of loss that determines what amplification prescription is appropriate. Hearing loss is not a uniform condition. A patient with a flat, moderate loss across all frequencies has entirely different amplification needs than a patient with a steeply sloping high-frequency loss at the same average threshold. An OTC hearing aid, by definition, cannot be programmed to an individual audiogram — it relies on generic amplification curves or simplified self-fitting adjustments that approximate a prescription without achieving it. Research on OTC hearing aids, while still emerging, suggests that prescription hearing aids fitted to validated audiometric targets consistently outperform OTC alternatives on objective speech recognition measures, particularly in complex listening environments.
What OTC Products Can and Cannot Do
OTC hearing aids vary considerably in their technology, quality, and sophistication. Some, such as products from Sony and Jabra, represent genuine hearing health technology developed by established manufacturers and offer reasonable performance for mild, high-frequency loss in quiet conditions. Others are amplifiers with limited sound processing and poor noise management that will likely frustrate users in any background noise. The regulatory category defines minimum technical standards but does not ensure clinical adequacy for any individual user. Consumer reviews and marketing materials are not substitutes for audiometric validation.
What OTC products genuinely offer is convenience and cost. A pair of OTC hearing aids typically costs between $200 and $1,600 — substantially less than prescription hearing aids, which range from approximately $1,500 to $7,000 per pair at current market rates. For a person with documented mild hearing loss who has already undergone audiological evaluation, is not a candidate for complex programming, and is seeking a basic amplification solution for a defined set of listening situations, an OTC product may be a reasonable choice. The clinical concern arises when OTC devices are substituted for evaluation and professional care in patients who actually need both, which given the unreliability of self-assessment, is a larger proportion of the OTC market than the FDA’s intended scope would suggest.
Real-Ear Measurement and Why It Matters
One of the most significant clinical differences between prescription and OTC hearing aid fittings is real-ear measurement verification. In a professional fitting, the audiologist places a thin probe microphone in the ear canal to confirm that the device is delivering the prescribed acoustic gain at each frequency — a procedure that takes the individual ear canal acoustics, eardrum impedance, and residual canal volume into account. This verification step is essential because even when a device is programmed to a target prescription, the actual sound level at the eardrum varies depending on the individual ear’s physical characteristics. Without measurement, the fitting is based on the manufacturer’s generic prediction, which research shows matches the real-ear target only about a third of the time. OTC hearing aids cannot be verified with real-ear measurement by the consumer; the technology and expertise required for that step are explicitly part of the professional service model.
This does not mean that every OTC user is poorly served — some may happen to have ear canal characteristics that align reasonably well with the device’s default curve, and some will benefit from even approximate amplification of frequencies they had been missing. But the absence of verification means that the user has no reliable way to know whether the device is meeting their prescription, underamplifying, or in some cases overamplifying at certain frequencies in a way that might damage residual hearing over time. This uncertainty is an inherent limitation of the OTC model that consumers should understand before choosing that path.
The audiological profession’s position is not that OTC hearing aids have no value — it is that they are not a substitute for evaluation, and that the decision about which path is appropriate should be an informed one. Starting with a professional audiological evaluation, establishing a clear baseline of hearing function, and then making an informed decision about intervention — whether prescription or OTC — is the approach most likely to serve the patient’s long-term hearing health. The evaluation is the investment; the device is the implementation.